Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Surgery, and aGVHD), Cell Source (Adipose tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs) - Global Forecasts to 2021
Click here for an in-depth analysis of the COVID-19 impact on the Stem Cell Therapy Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Stem Cell Therapy Market
Request Now[120 Pages Report] The global stem cell therapy market is a highly competitive market. This market is estimated to reach USD 145.76 million by 2021 from USD 86.5 million in 2016, at a CAGR of 11.0% during the forecast period. Growth in the stem cell therapy market is fuelled by the increasing number of scientific research activities focused on utilizing the therapeutic potency of stem cells for disease treatment, and the introduction of stem cell line banking. The development of induced pluripotent stem cell (iPSC) lines has also contributed to the growth of this market. The growing socio-ethical issues associated with embryonic stem cells have led to the increased adoption of iPSCs as alternatives.
By therapeutic applications, the musculoskeletal disorders segment is expected to be the largest segment of the market
On the basis of therapeutic applications, the stem cell therapy market is classified into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, gastrointestinal diseases, surgery, and other therapeutic applications. The musculoskeletal disorders segment dominates the global stem cell therapy market in 2016, owing to factors such as larger number of commercialized stem cell therapy products for the treatment of musculoskeletal disorders and the increasing prevalence of musculoskeletal disorders (coupled with the growth in geriatric population).
On the basis of cell sources, the adipose tissue-derived MSCs segment dominates the global stem cell therapy market in 2016
On the basis of cell source, the stem cell therapy market is segmented into adipose tissue-derived mesenchymal stem cells (MSCs), bone marrow-derived MSCs, cord blood/embryonic stem cells (SCs), and other stem cell lines. The adipose tissue-derived MSCs segment dominates the global stem cell therapy market in 2016. The growth of this segment is attributed to the growing demand for easy and accessible stem cell source and wide range of therapeutic applications offered by adipose tissue-derived stem cells. However, the bone marrow-derived MSCs segment is projected to witness the highest CAGR during the forecast period. Growth in this segment is driven by the increasing number of products launched based on bone-marrow derived MSCs, easy availability of cell source for harvesting cells, and less complications associated with the processing of bone marrow-derived MSCs.
North America dominated the market in 2016
North America (comprising the US and Canada) accounts for the largest share of the global stem cell therapy market in 2016, followed by Asia-Pacific. Factors such as rising public awareness related to the therapeutic potency of stem cells in disease therapy, growing number of clinical trials that aim to evaluate the therapeutic potential of stem cell-based products, increasing public-private funding & research grants for developing safe and effective stem cell therapy products, and growing patient base for target diseases (such as cancer, leukemia, neurodegenerative disorders, cardiovascular diseases, and gastrointestinal diseases) are driving the growth of the North American stem cell therapy market.
Market Dynamics
Stem cell therapies possess significant potential in the treatment of various diseases and injuries. With several public and private organizations playing an active role in funding and encouraging stem cell-based research programs, the global stem cell therapy market is expected to grow at a significant pace during next decade. The stem cell therapy market comprises a range of stem cell-based products which are utilized for the treatment of various diseases such as cancer, acute graft-vs-host disease (GvHD), tissue regeneration, as well as wounds and injuries
Stem cell therapy has been acclaimed to bring significant and revolutionary changes in the field of disease management strategies and patient care. These products offer effective treatment of conditions such as cancer, aGVHD, and vascular diseases. In recent years, stem cell therapy has been considered as a promising candidate in the field of regenerative medicine for the replacement or regeneration of damaged tissues. Moreover, there is growing awareness in the industry related to the therapeutic potency of stem cell for effective disease management. This is supported by the rising number of clinical trials and successful research studies that aim to validate the therapeutic potential of stem cell-based products. Few of the recent clinical trials are mentioned below:
- Xuzhou Medical University (China) initiated an interventional study in 2016 (last updated in October 2016). This study is aimed at the therapeutic evaluation of adipose-derived stem cells or fat cells for facial rejuvenation.
- The Affiliated Hospital of Academy of Military Medical Sciences (China) initiated an interventional phase 1 and phase 2 study in collaboration with Ivy Institute of Stem Cells Co. Ltd (China) in 2015 (last updated in March 2016). The study is aimed at testing the safety and efficacy of umbilical cord-derived mesenchymal stem cells (UC-MSCs) for treatment of patients with chronic heart ischemia cohort.
- Celal Bayar University (Turkey) initiated an interventional phase 1 study in collaboration with the Scientific and Technological Research Council (Turkey) and Acýbadem Labcell (Turkey) in 2016 (last updated in July 2016). The study is aimed at determining the safety and efficacy of mesenchymal stem cells derived from autologous adipose tissue for the treatment of chronic autoimmune urticaria.
Moreover, there are 5,888 active NIH-registered stem cell-based clinical trials being conducted worldwide. These clinical trials are expected to augment the consumer adoption and physician preference for stem cell therapies across major markets. This is expected to drive the demand growth for stem cell therapy products worldwide during the forecast period
Restraint: Socio-ethical issues related to the use of ESCs in disease treatment
Stem cell therapy makes use of living cells for the development of products used in a wide range of therapeutic applications. It is widely used for developing regenerative medicine for tissue and organ regeneration to cater to the growing demand for organ transplantation across the globe. However, the use of stem cells inside the human body is associated with several biosafety concerns; also, some religions do not accept defiling of the human body due to religious principles.
A number of ethical issues are associated with the use of stem cells in as these cells are derived by destructing the human embryo. The human embryo is viewed as potential life, and destroying it is considered to unethical even if it can save a human life. Such concerns related to the use of embryonic stem cells for developing stem cell therapy is a major factor restraining the market growth across the globe.
Scope of the Report
|
Report Metric |
Details |
|
Market Size Available for Years |
2014-2021 |
|
Base Year Considered |
2015 |
|
Forecast Period |
2016-2021 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Type, therapeutic application, cell source, and region |
|
Geographies Covered |
North America, Europe, APAC, and the RoW |
|
Companies Covered |
Osiris Therapeutics, Inc. (US), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate Srl (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (US), RTI Surgical, Inc. (US), and AlloSource (US) |
This report categorizes the stem cell therapy market into the following segments and subsegments:
Global Stem Cell Therapy Market, by Type
- Allogeneic Stem Cell Therapy Market, By Application
- Musculoskeletal Disorders
- Wounds and Injuries
- Surgeries
- Acute Graft-Versus-Host Disease (AGVHD)
- Other Applications
- Autologous Market, By Application
- Wounds and Injuries
- Cardiovascular Diseases
- Gastrointestinal Diseases
- Other Applications
Global Stem Cell Therapy Market, by Therapeutic Application
- Musculoskeletal Disorders
- Wounds and Injuries
- Cardiovascular Diseases
- Surgeries
- Gastrointestinal Diseases
- Other Applications
Global Stem Cell Therapy Market, By Cell Source
- Adipose Tissue-Derived Mesenchymal Stem Cells
- Bone Marrow-Derived Mesenchymal Stem Cells
- Cord Blood/Embryonic Stem Cells
- Other Cell Sources
Global Stem Cell Therapy Market, by Region
- North America
- Europe
- Asia Pacific
- Rest of the World (RoW)
Key Market Players
As of 2015, the global stem cell therapy market was dominated by Osiris Therapeutics, Inc. (US), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (US), RTI Surgical, Inc. (US), and AlloSource (US) among others.
Osiris Therapeutics, Inc. (US) held the leadership position in the global stem cell therapy market in 2015. The company’s product portfolio includes allogeneic stem cell-based products for musculoskeletal disorders (such as Bio4) and wounds and injuries application (such as Grafix, Stravix, and TruSkin). The company has a strong geographic presence in North American market. It primarily focuses on product development and commercialization to increase its revenue and strengthen its market position. The market has witnessed several product launches by Osiris Therapeutics in the last three years, such as Stravix (November 2015), TruSkin (November 2015), and Grafix (July 2014). This expanded the company’s stem cell-based product portfolio and strengthened its revenue base in stem cell therapy market.
MEDIPOST Co., Ltd. (South Korea) held the second position in the global stem cell therapy market in 2015. The company has a strong foothold in the stem cell therapy market. The company offers stem cell therapy product for musculoskeletal disorder (such as CARTISTEM). Furthermore, the company has diverse product pipeline in developmental phase. The company focuses on expanding its presence in the global stem cell therapy market by opting expansion strategy. In line with this, the company partnered with JingYuan Bio Ltd. (China), established a joint venture—OrLife Bio. (December 2014), entered into an agreement with Alkem Laboratories Ltd. (India) for commercialization of CARTISTEM (December 2013), and established MEDIPOST Hong Kong (its corporate office in Hong Kong) (January 2013). Additionally, the company focuses on organic growth strategy such as product development and commercialization to expand its product portfolio and strengthen its revenue base in stem cell therapy market. In line with this strategy the company received the Orphan Drug designation for its product PNUEMOSTEM (December 2013) and launched its new stem cell therapy product for musculoskeletal disorder namely, CARTISTEM (January 2012).
Recent Developments:
- In July 2016, JCR Pharmaceuticals signed a pharmaceutical development agreement with Medipal Holdings Corporation (Japan). JCR Pharmaceuticals received R&D funding for two drug programs from Medipal Holdings Corporation, and in return, Medipal Holdings Corporation received a fixed percentage of sales in Japan after the products were launched. This agreement helped JCR Pharmaceuticals to expand its distribution facilities in the Asian stem cell therapy market
- In April 2016, JCR Pharmaceuticals completed the construction of its new Clinical Trial Material Manufacturing Center (CTMC) and Cell Processing Center (CPC) at its research institute located in Kobe, Japan. The CPC facility is designed to manufacture raw materials required for preclinical and clinical trials of cell therapy and regenerative medicinal products.
- In November 2015, JCR Pharmaceuticals established JCR International SA, its new subsidiary in Fribourg, Switzerland. This helped the company to expand its presence in Europe.
- In November 2015, Osiris Therapeutics launched Stravix, a cryopreserved human placental tissue designed for soft tissue repair specifically in surgical procedures. Stravix comprises amniotic and connective layers of the umbilical tissue along with viable mesenchymal stem cells and growth factors.
Key questions addressed in the report:
- What are the growth opportunities related to stem cell therapy market across major regions in the future?
- Emerging countries have immense opportunities for the growth and adoption of stem cell therapy. Will this scenario continue in the next five years?
- What are the market shares of allogenic and autologous stem cell therapy in the overall market?
- What are the new trends and advancements in the allogenic and autologous stem cell therapy segment?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 15)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Markets Covered
1.3.1 Years Considered for the Study
1.4 Currency Used
1.5 Stakeholders
2 Research Methodology (Page No. - 17)
2.1 Research Methodology Steps
2.2 Secondary Research
2.3 Primary Research
2.4 Market Size Estimation Methodology
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Market Breakdown and Data Triangulation
2.6 Research Assumptions
2.7 Research Limitations
3 Executive Summary (Page No. - 26)
4 Premium Insights (Page No. - 30)
5 Market Overview (Page No. - 34)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Market Growth Drivers
5.2.1.1 Growing Awareness Related to the Therapeutic Potency of Stem Cells in Effective Disease Management
5.2.1.2 Development of Advanced Genome-Based Cell Analysis Techniques
5.2.1.3 Increasing Public-Private Investments for the Development of Stem Cell Therapies
5.2.1.4 Development in Infrastructure Related to Stem Cell Banking and Processing
5.2.2 Market Restraints
5.2.2.1 Unclear Regulatory Guidelines for Product Development & Commercialization
5.2.2.2 Socio-Ethical Issues Related to the use of ESCS in Disease Treatment
5.2.3 Market Growth Opportunities
5.2.3.1 Supportive Regulations Across Developing Countries
5.2.3.2 Emergence of IPSCS as an Effective Alternative to ESCS
5.2.4 Market Challenges
5.2.4.1 Technical Limitations Related to Production Scale-Up
5.3 Regulatory Landscape
5.3.1 North America
5.3.2 Europe
5.3.3 Asia-Pacific
5.3.4 Rest of the World
6 Industry Insights (Page No. - 46)
6.1 Introduction
6.2 Supply Chain Analysis
6.2.1 Key Stakeholders
6.2.2 Key Influencers
6.3 Pipeline Analysis
6.3.1 Pipeline Analysis: Based on Phase of Clinical Study
6.3.2 Pipeline Analysis: Based on Type
6.3.3 Pipeline Analysis: Based on the Cell Line Used
7 Global Stem Cell Therapy Market, By Type (Page No. - 52)
7.1 Introduction
7.2 Allogeneic Stem Cell Therapy Market, By Application
7.2.1 Musculoskeletal Disorders
7.2.2 Wounds and Injuries
7.2.3 Surgeries
7.2.4 Acute Graft-Versus-Host Disease (AGVHD)
7.2.5 Other Applications
7.3 Autologous Stem Cell Therapy Market, By Application
7.3.1 Wounds and Injuries
7.3.2 Cardiovascular Diseases
7.3.3 Gastrointestinal Diseases
7.3.4 Other Applications
8 Global Stem Cell Therapy Market, By Therapeutic Application (Page No. - 65)
8.1 Introduction
8.2 Musculoskeletal Disorders
8.3 Wounds and Injuries
8.4 Cardiovascular Diseases
8.5 Surgeries
8.6 Gastrointestinal Diseases
8.7 Other Applications
9 Global Stem Cell Therapy Market, By Cell Source (Page No. - 73)
9.1 Introduction
9.2 Adipose Tissue-Derived Mesenchymal Stem Cells
9.3 Bone Marrow-Derived Mesenchymal Stem Cells
9.4 Cord Blood/Embryonic Stem Cells
9.5 Other Cell Sources
10 Stem Cell Therapy Market, By Region (Page No. - 78)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 UK
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East & Africa
11 Competitive Landscape (Page No. - 92)
11.1 Introduction
11.2 Stem Cell Therapy Market Share Analysis, By Top 3 Global Players (In Terms of %Revenue Share as of 2015)
11.3 Competitive Scenerio (2012-2016)
11.3.1
11.3.2 Partnerships and Collaborations
11.3.3 Mergers and Acquisitions
11.3.4 Expansions
11.4 Competitive Leadership Mapping (For 25 Major Market Players)
11.4.1 Vendor Inclusion Criteria
11.4.1.1 Visionary Leaders
11.4.1.2 Innovators
11.4.1.3 Dynamic Differentiators
11.4.1.4 Emerging Companies
11.5 Competitive Leadership Mapping (For Start-Ups/Emerging Companies)
11.5.1 Vendor Inclusion Criteria
11.5.1.1 Progressive Companies
11.5.1.2
11.5.1.3 Responsive Companies
11.5.1.4 Dynamic Companies
12 Company Profiles (Page No. - 98)
12.1 Introduction
12.1.1 Geographic Benchmarking
(Overview, Financials, Products & Services, Strategy, and Developments)*
12.2 Osiris Therapeutics, Inc.
12.3 MEDIPOST Co., Ltd.
12.4 Anterogen Co., Ltd.
12.5 Pharmicell Co., Ltd.
12.6 Holostem Terapie Avanzate SRL
12.7 JCR Pharmaceuticals Co., Ltd.
12.8 NuVasive, Inc.
12.9 RTI Surgical, Inc.
12.10 Allosource
*Details on Overview, Financials, Product & Services, Strategy, and Developments Might Not be Captured in Case of Unlisted Companies.
13 Appendix (Page No. - 113)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Introducing Rt: Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports
13.7 Author Details
List of Tables (60 Tables)
Table 1 Few of the Recently Launched Cell Analysis Products (2015-2017)
Table 2 North America: Regulatory Landscape for Stem Cell Therapy (As of 2016)
Table 3 Europe: Regulatory Landscape for Stem Cell Therapy (As of 2016)
Table 4 Asia-Pacific: Regulatory Landscape for Stem Cell Therapy (As of 2016)
Table 5 RoW: Regulatory Landscape for Stem Cell Therapy (As of 2016)
Table 6 Global Stem Cell Therapy Market Size, By Type, 2014-2021 (USD Million)
Table 7 Global Allogeneic Stem Cell Therapy Market Size, By Application, 2014-2021 (USD Million)
Table 8 Global Allogeneic Stem Cell Therapy Market Size, By Region, 2014-2021 (USD Million)
Table 9 Allogeneic Stem Cell Therapy Market Size for Musculoskeletal Disorders, By Region, 2014-2021 (USD Million)
Table 10 Allogeneic Stem Cell Therapy Market Size for Wounds and Injuries, By Region, 2014-2021 (USD Million)
Table 11 Allogeneic Stem Cell Therapy Market Size for Surgeries, By Region, 2014-2021 (USD Million)
Table 12 Allogeneic Stem Cell Therapy Market Size for Acute Graft-Versus-Host Disease, By Region, 2014-2021 (USD Million)
Table 13 Allogeneic Stem Cell Therapy Market Size for Other Applications, By Region, 2014-2021 (USD Million)
Table 14 Global Autologous Stem Cell Therapy Market Size, By Application, 2014-2021 (USD Million)
Table 15 Global Autologous Stem Cell Therapy Market Size, By Region, 2014-2021 (USD Million)
Table 16 Autologous Stem Cell Therapy Market for Wounds and Injuries, By Region, 2014-2021 (USD Million)
Table 17 Autologous Stem Cell Therapy Market Size for Cardiovascular Diseases, By Region, 2014-2021 (USD Million)
Table 18 Autologous Stem Cell Therapy Market Size for Gastrointestinal Diseases, By Region, 2014-2021 (USD Million)
Table 19 Autologous Stem Cell Therapy Market Size for Other Applications, By Region, 2014-2021 (USD Million)
Table 20 Global Stem Cell Therapy Market Size, By Therapeutic Application, 2014-2021 (USD Million)
Table 21 Stem Cell Therapy Market Size for Musculoskeletal Disorders, By Region, 2014-2021 (USD Million)
Table 22 Stem Cell Therapy Market Size for Wounds and Injuries, By Region, 2014-2021 (USD Million)
Table 23 Stem Cell Therapy Market Size for Cardiovascular Diseases, By Region, 2014-2021 (USD Million)
Table 24 Stem Cell Therapy Market Size for Surgeries, By Region, 2014-2021 (USD Million)
Table 25 Stem Cell Therapy Market Size for Gastrointestinal Diseases, By Region, 2014-2021 (USD Million)
Table 26 Stem Cell Therapy Market Size for Other Applications, By Region, 2014-2021 (USD Million)
Table 27 Global Stem Cell Therapy Market Size, By Cell Source, 2014-2021 (USD Million)
Table 28 Stem Cell Therapy Market Size for Adipose Tissue-Derived MSCS, By Region, 2014-2021 (USD Million)
Table 29 Stem Cell Therapy Market Size for Bone Marrow-Derived MSCS, By Region, 2014-2021 (USD Million)
Table 30 Stem Cell Therapy Market Size for Cord Blood/Embryonic Stem Cells, By Region, 2014-2021 (USD Million)
Table 31 Stem Cell Therapy Market Size for Other Cell Sources, By Region, 2014-2021 (USD Million)
Table 32 Stem Cell Therapy Market Size, By Region, 2014-2021 (USD Million)
Table 33 North America: Stem Cell Therapy Market Size, By Type, 2014-2021 (USD Million)
Table 34 North America: Stem Cell Therapy Market Size, By Therapeutic Applications, 2014-2021 (USD Million)
Table 35 North America: Stem Cell Therapy Market Size, By Cell Source, 2014-2021 (USD Million)
Table 36 Europe: Stem Cell Therapy Market Size, By Type, 2014-2021 (USD Million)
Table 37 Europe: Stem Cell Therapy Market Size, By Therapeutic Application, 2014-2021 (USD Million)
Table 38 Europe: Stem Cell Therapy Market Size, By Cell Source, 2014-2021 (USD Million)
Table 39 Asia-Pacific: Stem Cell Therapy Market Size, By Type, 2014-2021 (USD Million)
Table 40 Asia-Pacific: Stem Cell Therapy Market Size, By Therapeutic Application, 2014-2021 (USD Million)
Table 41 Asia-Pacific: Stem Cell Therapy Market Size, By Cell Source, 2014-2021 (USD Million)
Table 42 RoW: Stem Cell Therapy Market Size, By Type, 2014-2021 (USD Million)
Table 43 RoW: Stem Cell Therapy Market Size, By Therapeutic Application, 2014-2021 (USD Million)
Table 44 RoW: Stem Cell Therapy Market Size, By Cell Source, 2014-2021 (USD Million)
Table 45 Top Product Launches and Approvals (2013–2016)
Table 46 Top Expansions (2013 – 2016)
Table 47 Top Agreements, Collaborations, and Partnerships (2013-2016)
Table 48 Osiris Therapeutics, Inc.: Stem Cell Therapy Products Offered
Table 49 Osiris Therapeutics, Inc.: Stem Cell Therapy Product Pipeline
Table 50 MEDIPOST Co., Ltd.: Stem Cell Therapy Products Offered
Table 51 MEDIPOST Co., Ltd.: Stem Cell Therapy Product Pipeline
Table 52 Anterogen Co., Ltd.: Stem Cell Therapy Products Offered
Table 53 Anterogen Co., Ltd.: Stem Cell Therapy Product Pipeline
Table 54 Pharmicell Co., Ltd.: Stem Cell Therapy Products Offered
Table 55 Pharmicell Co., Ltd.: Stem Cell Therapy Product Pipeline
Table 56 Holostem Terapie Avanzate SRL: Stem Cell Therapy Products Offered
Table 57 JCR Pharmaceuticals Co., Ltd.: Stem Cell Therapy Products Offered
Table 58 NuVasive, Inc.: Stem Cell Therapy Products Offered
Table 59 RTI Surgical, Inc.: Stem Cell Therapy Products Offered
Table 60 Allosource: Stem Cell Therapy Products Offered
List of Figures (37 Figures)
Figure 1 Research Design
Figure 2 Bottom-Up Approach
Figure 3 Top-Down Approach
Figure 4 Data Triangulation
Figure 5 Assumptions for the Study
Figure 6 Allogeneic Stem Cell Therapy Dominates the Stem Cell Therapy Market in 2016
Figure 7 Musculoskeletal Disorders Commands the Largest Share of the Stem Cell Therapy Market in 2016
Figure 8 Adipose Tissue-Derived MSCS Will Continue to Dominate the Stem Cell Therapy Market Till 2021
Figure 9 Stem Cell Therapy Market Share, By Region
Figure 10 Emerging Countries Offer High-Growth Opportunities to Players in the Stem Cell Therapy Market
Figure 11 Allogeneic Stem Cell Therapy to Dominate the Global Stem Cell Therapy Market During Forecast Period
Figure 12 Musculoskelatal Disorders Segment to Dominate the Global Stem Cell Therapy Market During Forecast Period
Figure 13 Adipose Tissue-Derived Cell Source Segment to Dominate the Stem Cell Therapy Market During Forecast Period
Figure 14 Growing Public Awareness Related to Therapeutic Potency of Stem Cells is Augmenting the Market Growth During the Study Period
Figure 15 Market Players Prefer Both Direct & Indirect Distribution Strategies for Stem Cell Therapy Products Across Major Geographies
Figure 16 Majority of Stem Cell Therapy Candidate Products are in Preclinical Phase, Followed By Phase 1 & Phase 1/2
Figure 17 Allogeneic Stem Cell Therapy Pipeline Products Account for a Larger Share of the Overall Stem Cell Therapy Products Under Development
Figure 18 Allogeneic Stem Cell Therapy Pipeline Products: Based on Study Phases
Figure 19 Autologous Stem Cell Therapy Pipeline Products: Based on Study Phases
Figure 20 Bone Marrow-Derived Mesenchymal Stem Cells are Preferred for Stem Cell Therapy Development
Figure 21 Allogeneic Stem Cell Therapy to Dominate the Global Stem Cell Therapy Market Till 2021
Figure 22 Musculoskelatal Disorders to Dominate the Allogeneic Stem Cell Therapy Market Till 2021
Figure 23 Wounds and Injuries Market to Dominate the Autologous Stem Cell Therapy Market Till 2021
Figure 24 Musculoskelatal Disorders Segment to Dominate Global Stem Cell Therapy Market Till 2021
Figure 25 Adipose Tissue-Derived Mesenchymal Stem Cells to Dominate the Global Stem Cell Therapy Market Till 2021
Figure 26 North America: Stem Cell Therapy Market Snapshot
Figure 27 Europe: Stem Cell Therapy Market Snapshot
Figure 28 Asia Pacific: Stem Cell Therapy Market Snapshot
Figure 29 RoW: Stem Cell Therapy Market Snapshot
Figure 30 Global Stem Cell Therapy Market Ranking (2015)
Figure 31 Product Development and Commercialization: the Key Growth Strategy Adopted By Stem Cell Therapy Market Players (2013-2016)
Figure 32 Product Launches and Enhancements: Key Strategy Adopted By Majority of Key Players During Study Period
Figure 33 Geographic Revenue Mix of the Top Five Players (2015)
Figure 34 MEDIPOST Co., Ltd.: Company Snapshot (2015)
Figure 35 JCR Pharmaceuticals Co., Ltd.: Company Snapshot (2015)
Figure 36 NuVasive, Inc.: Company Snapshot (2015)
Figure 37 RTI Surgical, Inc.: Company Snapshot (2015)
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Stem Cell Therapy Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Stem Cell Therapy Market